Title: PYRIDOPYRAZINONES DERIVATIVES INSULIN SECRETION STIMULATORS, METHODS FOR OBTAINING THEM AND USE THEREOF FOR THE TREATMENT OF DIABETES

Abstract: The present invention relates to pyridopyrazinone derivatives of formula (I), wherein X, Y, Z1 W, A and R1 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.
Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Field of the invention
The present invention relates to pyridopyrazinone derivatives of formula (I) as insulin secretion stimulators. The invention also relates to the preparation and use of these pyridopyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.

Background of the invention
Type 2 diabetes mellitus is one of the most common worldwide diseases. In 2007, its prevalence was estimated at 5.9 % (246 million people) of the adult population and is in continuous increase. This disease is even more serious since it could lead to severe micro- and macro-complications, which could become disabling or lethal, as diabetes is a major risk factor for cardiovascular disease and stroke.

Type 2 diabetes is characterized by a fasted and post-prandial hyperglycemia, consequence of two main defects: an insulin resistance at the level of target tissues and an altered insulin secretion from the pancreatic beta cells. This latter anomaly seems to appear very early as it is present at the Impaired Glucose Tolerance (IGT) stage (Mitrakou et al., N. Engl. J. Med. 326: 22-29, 1992). It has been observed in UK Prospective Diabetes Study (UKPDS) that 50% of the beta cell function is already lost when diabetes is diagnosed, suggesting that deterioration in beta cell function may begin 10-12 years before diabetes diagnosis (Holman, Diabetes Res. Chn. Pract. 40 : S21, 1998 or UKPDS Group, Diabetes 44: 1249-58, 1995).

The defective insulin secretion is due to a quantitative and a qualitative defect of the beta cell, i.e. a decreased beta cell mass and a specific defect of insulin release in response to glucose, especially the first phase of secretion, since the response to non-glucose secretagogues is preserved.
(Pfeifer et al., Am. J. Med. 70: 579-88, 1981). The importance of restoring a normal profile of insulin release in response to glucose to maintain the glycemic control within a normal range was supported by studies in non diabetic volunteers showing that delaying the first phase of insulin secretion in response to glucose led to glucose intolerance (Calles-Escandon et al., Diabetes 36: 1167-72, 1987).

Oral antidiabetics available for treatment of type 2 diabetic patients, such as sulfonylureas or glinides, are known to induce insulin secretion, by binding to sulfonylurea receptor on the K-ATP channels of the beta cell, leading to increase in intracellular calcium and insulin exocytosis. This insulin release is thus totally independent of the plasma glucose level and treatment with these molecules usually induces sustained hyperinsulinemia, which could lead to several side-effects, such as severe hypoglycaemia, body weight gain, and aggravation of cardiovascular risk. In addition, the prolonged hyperinsulinemia observed with sulfonylurea treatment, with no preservative effect of the beta cell mass, could lead to secondary failure due to beta cell exhaustion, another deleterious side effect of these compounds.

New treatment of type 2 diabetes should restore a normal profile of insulin release specifically in response to glucose, while preserving or increasing the beta cell mass. This is observed with GLP-1 analogs, such as exenatide or liraglutide, but these molecules are peptides and must be administered by parenteral route.

Such characteristics for a new oral small molecule would be a great advantage over the other antidiabetic drugs.

According to the present invention, the compounds of the formula (I) are insulin secretion stimulators, useful for treatment of diabetes and pathologies associated. They lower blood glucose levels by restoring the defective glucose-induced insulin secretion in type 2 diabetics.
The patent application WO 2007020521 discloses pyridopyrazinone derivatives as PDE V inhibitors.
EP 770079 discloses pyridopyrazinone derivatives as PDE IV and TNF inhibitors.
The patent application WO 2004031189 discloses pyridopyrazinone derivatives as corticotrophin releasing factor receptor antagonists, for treatment of anxiety and depression.
US 4296114 describes pyridopyrazinone derivatives as antiinflammatory agents.
None of the prior art discloses pyridopyrazinone derivatives with antidiabetic activity.

Summary of the invention
The present invention is directed towards pyridopyrazinone derivatives of formula (I). Said derivatives are useful for treating diabetes and pathologies associated therewith. Pyridopyrazinone derivatives according to the invention have the following formula (I):

![Chemical structure]

(I)

wherein:
one atom among X, Y, Z, W is a nitrogen atom and the others are a carbon atom substituted by a substituent selected from:
hydrogen,
T;
X is preferably N;
A is:
aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, arylthioalkyl, arylalkylthioalkyl, heteroarylalkyl, heteroaryloxyalkyl, heteroarylalkoxyalkyl, heteroarylthioalkyl, heteroarylalkylthioalkyl, heterocycloalkylalkyl, heterocycloalkyloxyalkyl, heterocycloalkylalkoxyalkyl, heterocycloalkylthioalkyl, heterocycloalkylalkylthioalkyl, arylakenyl, arylalkynyl; heteroaryl or heterocycloalkyl groups can include one or more heteroatom selected from N, O and S; each of these groups can be optionally substituted by one or more substituents selected from T;
preferably, A is:
aryl, aryalkyl, heteroaryl which can include one or more heteroatoms selected from N, O and S; each of these groups can be optionally substituted by one or more substituents selected from T;
more preferably, A is:
phenyl, benzyl, each of these groups can be optionally substituted by one or more substituents selected from T;
A is preferably aryl, more preferably phenyl;

R₁ is:
alkyl, alkyl氧xyalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkyloxyalkyl, heterocycloalkylalkoxyalkyl, heterocycloalkylthioalkyl, heterocycloalkylalkylthioalkyl, R₃R₄N-alkyl, aryl, heteroaryl, aryalkyl, heteroarylalkyl;
each of these groups can be optionally substituted by one or more substituents selected from T;
preferably, R₁ is:
alkyl, alkyl氧xyalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkyloxyalkyl, heterocycloalkylalkoxyalkyl, heterocycloalkylthioalkyl, heterocycloalkylalkylthioalkyl, heterocycloalkylalkylthioalkyl, each of these groups can be optionally substituted by one or more substituents selected from T;
more preferably, R₁ is:
is alkyl, alkyloxyalkyl, cycloalkyl, cycloalkylalkyl; each of these groups can be optionally substituted by one or more substituents selected from T; still more preferably, R1 is: ethyl; isopropyl; butyl; 2,2-difluoroethyl; 2-methoxyethyl; cyclopropyl; cyclopropylmethyl;

T is chosen without preference from the following groups: hydroxy, thio, halogen, cyano, trifluoromethoxy, trifluoromethyl, carboxy, carboxy methyle, carboxyethyle, alkyle, cycloalkyl, alkoxy, alkylamino, aryle, aryle sulfonylalkyl, aryloxy, aylalkoxy, NR3R4, azido, nitro, guanidino, amidino, phosphono, oxo, carbamoyle, alkylsulfonyl, alkylsulfinyl, alkylthio, SF5, two T groups can form a mehylenedioxy; preferably, T is: hydroxy, thio, halogen, cyano, trifluoromethoxy, trifluoromethyl, carboxy, carboxy methyle, carboxyethyle, alkyle, cycloalkyl, alkoxy, aryle, aryle sulfonylalkyl, aryloxy, aylalkoxy, NR3R4, azido, guanidino, amidino, phosphono, oxo, carbamoyle, alkylsulfonyl, alkylsulfinyl, alkylthio, SF5, two T groups can form a mehylenedioxy; more preferably, T is: halogen, trifluoromethyl, alkyle, alkoxy; still more preferably, T is: alkyl, cycloalkyl, Cl, F;

R3 and R4 are independently selected from: hydrogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R3 and R4 can also constitute an heterocycloalkyl group which can include one or more heteroatoms selected from N, O and S; R3 and R4 independently can be optionally substituted by one or more substituents selected from T; preferably, R3 and R4 are independently selected from lower alkyl, cycloalkyl;
as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof.

The compounds of the formula (I) may be chosen from:

1-cyclopropyl-3-(4-fluorophenyl)pyrido[3,4-b]pyrazin-2(1/-/-)-one
1-cyclopropyl-3-[4-(trifluoromethyl)phenyl]pyrido[3,4-b]pyrazin-2(1H)-one
1-cyclopropyl-3-phenylpyrido[3,4-b]pyrazin-2(1H)-one
2-(3-chlorophenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4/-/-/-)-one
2-(4-chloro-2-methylphenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4/-/-/-)-one
2-(4-chlorobenzyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4/-/-/-)-one
2-(4-chlorophenyl)-4-(2,2-difluoroethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropyl-6-methylpyrido[2,3-b]pyrazin-3(4/-/-/-)-one
2-(4-chlorophenyl)-4-cyclopropyl-7-methylpyrido[2,3-b]pyrazin-3(4/-/-/-)-one
2-(4-chlorophenyl)-4-cyclopropyl-8-methylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropylmethylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4/-/-/-)-one
2-(4-chlorophenyl)-4-ethylpyrido[2,3-b]pyrazin-3(4/-/-/-)-one
2-(4-chlorophenyl)-4-isopropyl-pyrido[2,3-b]pyrazin-3(4/-/-/-)-one
2-(4-chlorophenyl)-4-fluorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4/-/-/-)-one
2-(4-fluorophenyl)-4-ethylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-isopropyl-pyrido[2,3-b]pyrazin-3(4/-/-/-)-one
3-(4-chlorophenyl)-1-cyclopropylpyrido[3,4-b]pyrazin-2(1/-/-/-)-one
4-(2,2-difluoroethyl)-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-(2,2-difluoroethyl)-2-(4-trifluoromethylphenyl)pyrido[2,3-b]pyrazin-3(4/-/-/-)-one
4-(2,2-difluoroethyl)-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one
4-(2-methoxyethyl)-2-(4-trifluoromethylphenyl)-pyrido[2,3-b]pyrazin-3(4/-/-/-)-one
4-(2-methoxyethyl)-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one
4-(cyclopropylmethyl)-2-(4-fluoro-2-methylphenyl)pyrido[2,3-b]pyrazin-3(4/-/)-one
4-butyl-2-(4-chlorophenyl)-pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclobutyl-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(3-fluorophenyl)-pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(3-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluoro-2-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)-6-methoxypyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)-6-methylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)-7-methylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)-8-methylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-trifluoromethylphenyl)-8-methylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-trifluoromethylphenyl)-8-methylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-trifluoromethylphenyl)-pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(3-(trifluoromethyl)phenyl)pyrido[2,3-b]pyrazin-3(4/-/)-one
4-cyclopropyl-2-phenylpyrido[2,3-b]pyrazin-3(4/-/)-one
4-cyclopropylmethyl-2-(4-fluoro-2-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropylmethyl-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropylmethyl-2-(4-trifluoromethylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropylmethyl-2-(4-trifluoromethylphenyl)pyrido[2,3-b]pyrazin-3(4/-/)-one
4-cyclopropylmethyl-2-phenylpyrido[2,3-b]pyrazin-3(4/-/)-one
4-ethyl-2-phenylpyrido[2,3-b]pyrazin-3(4/-/)-one
4-isopropyl-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one
2-(2-Chlorophenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4/-/)-one
4-Cyclopropyl-2-(2,4-dichlorophenyl)pyrido[2,3-b]pyrazin-3(4/-/)-one
4-Cyclopropyl-2-(2,4,5-trifluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-Cyclopropyl-2-(2-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-Cyclopropyl-2-(4-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chloro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(2,4-Dichlorophenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Fluoro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(2-Ethoxyphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(6-methoxypyridin-3-yl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(2,4,5-trifluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-Cyclopropyl-2-(2-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-Cyclopropyl-2-(4-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chloro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Fluoro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(2-Ethoxyphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(2,4,5-trifluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(2-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chloro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Fluoro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(2-Ethoxyphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(2,4,5-trifluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(2-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chloro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Fluoro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(2-Ethoxyphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(2,4,5-trifluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(2-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chloro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Fluoro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(2-Ethoxyphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(6-methoxypyridin-3-yl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(2-thienyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(2-furyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Fluorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Fluorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-(3-Hydroxypropyl)-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(3-hydroxypropyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(3-hydroxypropyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
1-ethyl-3-(4-fluorophenyl)pyrido[2,3-b]pyrazin-2(1H)-one
as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof.
More preferably, the compounds of the formula (I) according to the invention may be chosen from:

2-(4-chlorobenzyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4/-/)-one
2-(4-chlorophenyl)-4-(2,2-difluoroethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-(cyclopropylmethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropylmethylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-ethylpyrido[2,3-b]pyrazin-3(4/-/)-one
2-(4-chlorophenyl)-4-isopropyl-pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4/-/)-one
4-cyclopropyl-2-ethylpyrido[2,3-/?]pyrazin-3(4/-/)-one
4-cyclopropylmethyl-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-ethyl-2-phenylpyrido[2,3-fe]pyrazin-3(4/-/)-one

as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof.

The invention also relates to the racemic forms, tautomeric forms, enantiomers, diastereoisomers, epimers and organic or mineral salts of the compounds of the general formula (I), as well as their crystalline forms, including their polymorphic forms and the polymorphic forms of the compounds of formula (I).

The present invention is directed not only to racemic mixtures of these compounds, but also to individual stereoisomers and/or diastereoisomers thereof as well or as mixtures of these in all proportions.

The compounds of the invention of the formula (I), as defined above, containing a sufficiently acidic function or a sufficiently basic function, or both,
may include the corresponding pharmaceutically acceptable salts of an organic or mineral acid or of an organic or mineral base.

The expression "pharmaceutically acceptable salts" refers to the relatively non-toxic mineral and organic acid-addition salts, and the base-addition salts, of the compounds of the present invention. These salts may be prepared in situ during the final isolation and purification of the compounds.

In particular, the acid-addition salts may be prepared by separately reacting the purified compound in its purified form with an organic or mineral acid and isolating the salt thus formed. The resulting salts are, for example, hydrochlorides, hydrobromides, sulfates, hydrogenosulfates, dihydrogenophosphates, citrates, maleates, fumarates, trifluoroacetates, 2-naphhtalenesulfonates, para-toluenesulfonates.

The invention also relates to pharmaceutically acceptable salts with organic or inorganic bases. In particular, the basic-addition salts may be prepared by separately reacting the purified compound in its purified form with an organic or inorganic base and isolating the salt thus formed. The resulting salts are, for example, metal salts, particularly alkali metal salts, alkaline-earth metal salts and transition metal salts (such as sodium, potassium, calcium, magnesium, aluminum), or salts obtained with bases, such as ammonia or secondary or tertiary amines (such as diethylamine, triethylamine, piperidine, pipеразине, morpholine), or with basic amino-acids, or with osamines (such as meglumine), or with aminoalcohols (such as 3-aminobutanol and 2-aminoethanol).

The invention also relates to the salts used for chiral resolution of the racemates.

As examples, the following chiral acids can be used: (+)-D-di-O-benzoyltartaric acid, (-)-L-di-O-benzoyltartaric acid, (-)-L-di-O,O'-p-toluyl-L-tartaric acid, (+)-D-di-O,O'-p-toluyl-L-tartaric acid, (R)-(+)malic acid, (S)-(−)-malic acid, (+)-camphoric acid, (-)-camphoric acid, R(-)-1,1'-binaphtalen-2,2'-diyl hydrogenophosphonic, (+)-camphamic acid, (-)-camphamic acid, (S)-(+)2-phenylpropionic acid, (R)-(+)2-phenylpropionic acid, D-(−)-mandelic acid, L-(+)mandelic acid, D-tartaric acid, L-tartaric acid, or any mixture of them.
As examples, the following chiral amines can be used: quinine, brucine, (S)-1-(benzyloxymethyl)propylamine (III), (-)-ephe drine, (4S,5R)-(+) -1,2,2,3,4-tetramethyl-5-phenyl-1,3-ox azolidine, (R)-1-phenyl-2-p-tolylethylamine, (S)-phenylglycinol, (-)-N-methylephedrine, (+)-(2S,3R)-4-dimethylamino-3-methyl-1,2-diphenyl-2-butanol, (S)-phenylglycinol, (S)-α-methylbenzylamine or any mixture of them.

Also included in the scope of the present invention are prodrugs of the compounds of formula (I).

The term "prodrug" as used herein refers to any compound that when administered to a biological system generates the "drug" substance (a biologically active compound) as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), and/or metabolic chemical reaction(s).

In accordance with the present invention and as used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.

The term "aryl" refers to aromatic groups which have 5-14 ring atoms and at least one ring having a conjugated π (π) electron system and includes biaryl groups, all of which may be optionally substituted. Suitable aryl groups include phenyl, naphthyl, biphenyl, anthryl, phenanthryl, indenyl and the like.

The term "heteroaryl" refers to 5-14 ring atom aromatic heterocycles containing 1 to 4 heteroatoms as ring atoms in the aromatic ring and the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include O, S, N. Suitable heteroaryl groups include furanyl, benzofuranyl, thienyl, pyridyl, pyridyl-N-oxide, pyrimidinyl, pyrazinyl, oxazolyl, thiazolyl, isoxazolyl, quinolinyl, triazolyl, pyridazinyl, pyrrolyl, imidazolyl, indazolyl, isothiazolyl, indolyl, oxadiazolyl and the like.
The term "cycloalkyl" means saturated carbocyclic rings, optionally substituted, and includes mono-, bi- and tri-cyclic compounds with 3 to 10 carbon atoms. Suitable cycloalkyl groups are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, adamantyl and the like.

The term "heterocycloalkyl" refers to optionally substituted monocyclic, bicyclic or tricyclic radicals, comprising one or more heteroatoms, preferably chosen from among O, S and N, optionally in the oxidized state (for S and N), and optionally one or more double bonds. At least one of the rings preferably comprises from 1 to 4 endocyclic heteroatoms, more preferably from 1 to 3 heteroatoms. Most preferably, the heterocycloalkyl (or simply "heterocyclic") radical comprises one or more rings, each having from 5 to 8 nodes. Examples of heterocyclic radicals are: morpholinyl, piperidinyl, piperaziny1, thiazolidinyl, oxazolidinyl, tetrahydrothienyl, dihydrofuranyl, tetrahydrofuranyl, pyrazolidinyl, 1,3-dioxolanyl, pyrrolidinyl, pyranyl, dihydropyranly, isoxazolidinyl, imidazolyl, imidazolidinyl and the like.

The term "alkyl" refers to a saturated aliphatic groups, including straight chain and branched chain groups. Suitable alkyl groups, having 1 to 20 carbon atoms, include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, pentyl, hexyl, octyl, decanoyl, dodecanoyl, hexadecyl, octadecyl groups and the like.

The term "alkylene" refers to a divalent radial obtained from an alkyl radical after one hydrogen atom has been withdrawn.

The term "alkenyl" refers to unsaturated groups comprising at least one carbon-carbon double bond, and includes straight chain, branched chain and cyclic groups. Suitable alkenyl groups, having 2 to 20 carbon atoms, include ethenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl and the like.
The term "alkynyl" refers to unsaturated groups comprising at least one carbon-carbon triple bond and includes straight chain, branched chain and cyclic groups; and optionally includes at least one carbon-carbon double bond. Suitable alkynyl groups, having 2 to 20 carbon atoms, include ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl and the like.

The term "arylalkyl" refers to an alkyl group, preferably an alkyl group having 1 to 20 carbon atoms, substituted with an aryl group. Suitable arylalkyl groups include benzyl, picolyl, and the like.

The term "alkoxy" refers to the group alk-O- wherein "alk" is an alkyl group.

The term "aryloxy" refers to the group aryl-O-.

The term "aryloxyalkyl" refers to an alkyl group substituted with an aryloxy group.

The term "arylalkoxy alkyl" refers to an alkyl group substituted with an arylalkoxy group.

The term "arylalkoxy" refers to the group aryl-Alk-O-, wherein "Alk" is an alkyl group.

The term "arylthioalkyl" refers to an alkyl group substituted with an arylthio group.

The term "arylalkythioalkyl" refers to an alkyl group substituted with an arylalkythio.
The term "heteroarylalkyl" refers to an alkyl group substituted with a heteroaryl group.

The term "heteroaryloxyalkyl" refers to an alkyl group substituted with a heteroaryloxy group.

The term "heteroarylalkoxyalkyl" refers to an alkyl group substituted with a heteroarylalkoxy group.

The term "heteroarylthioalkyl" refers to an alkyl group substituted with a heteroarylthio group.

The term "heteroarylalkylthioalkyl" refers to an alkyl group substituted with a heteroarylalkylthio group.

The term "heterocycloalkylalkyl" refers to an alkyl group substituted with a heterocycloalkyl group.

The term "heterocycloalkyloxyalkyl" refers to an alkyl group substituted with a heterocycloalkyloxy group.

The term "heterocycloalkylalkoxyalkyl" refers to an alkyl group substituted with a heterocycloalkylalkoxy group.

The term "heterocycloalkylthioalkyl" refers to an alkyl group substituted with a heterocycloalkylthio group.

The term "heterocycloalkylalkylthioalkyl" refers to an alkyl group substituted with a heterocycloalkylalkylthio group.

The term "arylakenyl" refers to an alkenyl group substituted with an aryl group.
The term "arylalkynyl" refers to an alkynyl group substituted with an aryl group.

The term "alkyloxyalkyl" refers to an alkyl group substituted with an alkyloxy group.

The term "cycloalkylalkyl" refers to an alkyl group substituted with a cycloalkyl group.

The term "heterocycloalkylalkoxyalkyl" refers to an alkyl group substituted with a heterocycloalkyl group.

The term "heterocycloalkylalkoxyalkyl" refers to an alkyl group substituted with a heterocycloalkylalkoxy group.

The term "heterocycloalkylthioalkyl" refers to an alkyl group substituted with a heterocycloalkylthio group.

The term "heterocycloalkylalkylthioalkyl" refers to an alkyl group substituted with a heterocycloalkylalkylthio group.

The term "lower" referred to herein in connection with organic radicals or compounds respectively defines such as with up to and including 10, preferably up to and including 6, and advantageously one to four carbon atoms. Such groups may be straight, branched, or cyclic chain.

The term "aryle sulfonylalkyl" refers to the group aryle-SO₂-Alk wherein, "Alk" is an alkyl group.

The terms "alkylthio" refers to the group alkyl-S-, wherein "alk" is an alkyl group.
The term "halogen" refers to a fluorine, bromine or chlorine atom.

The term "amidino" refers to -C(NR3)-NR3R4 where R3R4 are as defined above, all, except hydrogen, are optionally substituted.

The invention's compounds according to formula (I) exhibit an hypoglycemic activity, and are useful in the treatment of pathologies associated with the syndrome of insulin resistance.

Insulin resistance is characterised by a reduction in the action of insulin (cf. "Presse Medicale", (1997), 26(14), 671-677) and is involved in many pathological conditions, such as diabetes and more particularly non-insulin-dependent diabetes (type II diabetes or NIDDM), dyslipidaemia, obesity, arterial hypertension, and also certain cardiac, microvascular and macrovascular complications, for instance atherosclerosis, retinopathy and neuropathy. In this respect, reference will be made, for Example, to Diabetes, 37, (1988), 1595-1607; Journal of Diabetes and its complications, 12, (1998), 110-119; Horm. Res., 38, (1992), 28-32.

The invention also relates to pharmaceutical composition containing as active ingredient at least one compound of formula (I), as defined above, and/or a pharmaceutically acceptable salt thereof, in combination with one or several pharmaceutically acceptable carrier, adjuvant, diluent or excipient. A person skilled in the art is aware of a whole variety of such carrier, adjuvant, diluent or excipient compounds suitable to formulate a pharmaceutical composition.

The pharmaceutical compositions of the present invention can be administered by a variety of routes including oral, parenteral, intravenous, intramuscular, rectal, permucous or percutaneous.

They will thus be presented in the form of injectable solutions or suspensions or multi-dose bottles, in the form of plain or coated tablets, sugar-coated tablets, wafer capsules, gel capsules, pills, sachets, powders, suppositories.
or rectal capsules, solutions or suspensions, for percutaneous use in a polar solvent, or for permucous use.

The excipients that are suitable for such administrations are pharmaceutically acceptable excipients, such as cellulose or microcrystalline cellulose derivatives, alkaline-earth metal carbonates, magnesium phosphate, starches, modified starches, lactose and the like for solid forms.

For rectal use, cocoa butter or polyethylene glycol stearates are the preferred excipients.

For parenteral use, water, aqueous solutions, physiological saline and isotonic solutions are the vehicles most appropriately used.

For example, in the case of an oral administration, for example in the form of granules, tablets or coated tablets, pills, capsules, gel capsules, gels, cachets or powders, a suitable posology of the compounds is between about 0.1 mg/kg and about 100 mg/kg, preferably between about 0.5 mg/kg and about 50 mg/kg, more preferably between about 1 mg/kg and about 10 mg/kg and most preferably between about 2 mg/kg and about 5 mg/kg of body weight per day.

If representative body weights of 10 kg and 100 kg are considered, in order to illustrate the daily oral dosage range that can be used and as described above, suitable dosages of the compounds of the formula (I) will be between about 1-10 mg/per day and 1000-10000 mg/per day, preferably between about 5-50 mg/per day and 500-5000 mg/per day, more preferably between 10-100 mg and 100-1000 mg/per day and most preferably between 20-200 mg and 50-500 mg/per day.

It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs which have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those skilled in the art.
As noted above, formulations of the present invention suitable for oral administration may be presented as discrete units, such as capsules, cachets or tablets, each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste.

The present invention also relates to compound of general formula (I) as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof, for the preparation of a medicament for the prevention and/or treatment of pathologies associated with hyperglycaemia; for the preparation of a medicament that induces insulin secretion in response of glucose concentration, preferably for the treatment of diabetes, more preferably for the prevention and/or treatment of type II diabetes and pathologies associated to metabolic disorders, hypercholesteremia, hyperlipidemia, which are increased by hyperinsulinemia and hyperglycemia; for the treatment of diseases chosen from diabetes related microvascular and macrovascular complications, such as arterial hypertension, inflammatory processes, microangiopathy, macroangiopathy, retinopathy and neuropathy; for reducing hyperglycaemia, for the treatment of dyslipidaemia and obesity; or diseases such as cardiovascular diseases, comprising atherosclerosis, myocardial ischemia.

The present invention also relates to the use of at least a compound of the general formula (I), as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts, and pro-drugs thereof, for the prevention and/or treatment of pathologies associated with hyperglycaemia, preferably for the treatment of diabetes, more preferably for the prevention and/or treatment of type II diabetes and pathologies associated to metabolic
disorders, hypercholesteremia, hyperlipidemia, which are increased by hyperinsulinemia and hyperglycemia; for the treatment of diseases chosen from diabetes related microvascular and macrovascular complications, such as arterial hypertension, inflammatory processes, microangiopathy, macroangiopathy, retinopathy and neuropathy; for reducing hyperglycaemia, for the treatment of dyslipidaemia and obesity; or diseases such as cardiovascular diseases, comprising atherosclerosis, myocardial ischemia.

The present invention also relates to manufacturing process of compounds of formula (I), as defined above, according to the following representative methods shown in Scheme 1 (Preparation of the Intermediates diaminopyridine derivatives); Scheme 2 (Method A) or Scheme 3 (Method B), in which X, Y, Z, W, R₁, A are as defined above in formula (I) and Hal is a halogen atom, preferably Cl or Br.

The following schemes are given for representative purposes, and solely for the purpose of facilitating the representation. Needless to say, depending on the nature of the compounds of the formula (I) to be obtained, the methodologies presented may be adapted by a person skilled in the art by selecting the appropriate starting materials, in which the nature of the substituents R₁ and A may be modified, especially as a function of the nature and length of the desired chain.

The compounds useful according to the invention may be prepared, unless specifically specified, by the application or adaptation of known methods, by which are meant methods used heretofore or described in the literature, patents or patent applications, the Chemical Abstracts and on the Internet.

**Preparation of the Intermediates diaminopyridine derivatives:**

**Scheme 1:**
wherein:
Hal is a halogen atom, preferably Cl, Br;
R₁ is as above defined in formula (I);
X, Y, Z and W are as above defined in formula (I).

Pyridine nitro amino derivatives of formula (2) are prepared by reacting an halo-nitropyridine derivative of formula (1) with an amine, in the presence of at least one equivalent of a base, such as sodium or potassium carbonate, cesium carbonate, or in the presence of at least two equivalents of the considered amine, in an inert solvent, such as tetrahydrofurane, acetonitrile or toluene, at a temperature between 20°C and the reflux for 1 to 24h.

Diamino pyridine derivatives of formula (3) may be prepared from compounds of formula (2) by reduction of the nitro to the corresponding primary aromatic amine. Preferred methods use metal, such as Zn, Sn or Fe, in acids, such as aqueous HCl. Other preferred method, use metal in lower state of oxidation, such as Sn(II)chloride in HCl. Particularly preferred is the reduction by catalytic hydrogenation, which uses metal catalysts from metals such as Pd, Pt or Ni, preferably Pd on charcoal or Raney Nickel in solvents such as methanol, ethanol, tetrahydrofurane.

**Preparation of the pyridopyrazinone derivatives:**

**Scheme 2 - Method A**
This method is particularly suitable for compounds of formula (I), wherein:

Rx is Hal, ORe (wherein Re is hydrogen, lower alkyl);

Hal is a halogen atom, preferably Cl, Br;

R1 is as above defined in formula (I);

A is as above defined in formula (I);

X, Y, Z and W are as above defined in formula (I).

Pyridopyrazinones of formula (I) are prepared by cyclization of compounds of formula (3) with an α- keto acid derivative in a solvent, such as, for example, methanol, acetonitrile, dimethylformamide (DMF) or toluene, at a temperature between 20°C and the reflux, more preferably reflux, for 1 to 36 h.

**Scheme 3 - Method B**

This method is particularly suitable for compounds of formula (I), wherein:

Rx is Hal, ORe (wherein Re is hydrogen, lower alkyl);
Hal is a halogen atom, preferably Cl, Br;
R 1 is as above defined in formula (I);
A is as above defined in formula (I);
X, Y, Z and W are as above defined in formula (I).

Hydroxypyridopyrazinones of formula (5) are obtained by cyclization of compounds of formula (3) with, for example, chloro(oxo)acetate derivatives in the presence of at least one equivalent of a base, an inorganic base, such as sodium or potassium carbonate, cesium carbonate, or an organic base, such as triethylamine or diisopropylethylamine, in an inert solvent, such as, for example, dichloromethane, acetonitrile, DMF, at a temperature between 20°C and the reflux, for 1 to 24h.

Bromo derivatives of formula (6) are prepared by bromination of compounds of formula (5) using a brominating agent, such as POBr₃, in an inert solvent, such as 1,2-dichloroethane, at a temperature between 20°C and the reflux, more preferably reflux for 1 to 24h.

Pyridopyrazinones of formula (I) are prepared by reacting the bromo compounds of formula (6) with boronic acid derivatives or their esters, in the presence of a base, such as sodium carbonate or potassium carbonate, and a catalyst, such as bis(triphenylphosphine) palladium(II)chloride, in an inert solvent, such as dimethylformamide or toluene, at a temperature between 20°C and the reflux, more preferably reflux, for 1 to 24h.

The examples that follow illustrate the invention without, however, limiting it.

The starting materials used are known products or products prepared according to known procedures. The percentages are expressed on a weight basis, unless otherwise mentioned.

The compounds were characterised especially via the following analytical techniques.

The NMR spectra were acquired using a Bruker Avance DPX 300 MHz NMR spectrometer.
The masses were determined by HPLC coupled to an Agilent Series 1100 mass detector. The melting points (m.p.) were measured on a Stuart Scientific block.

**Examples:**

**Example 1:** *N*-(cyclopropylmethyl)-3-nitropyridin-2-amine

\[
\begin{align*}
\text{Cl} & \quad \text{NH} \\
\text{NO}_2 & \quad \text{NH} \\
\end{align*}
\]

3 g (18.9 mM) of 2-chloro-3-nitropyridine and 5 g (70.3 mM) of cyclopropylmethylamine in 12 ml of tetrahydrofurane were refluxed under stirring for 1 h. Water was added and the aqueous layer was extracted with ethylacetate. The organic layer was washed with water and dried over anhydrous sodium sulfate. The solvent was removed under vacuum to give 3.5 g of *N*-(cyclopropylmethyl)-3-nitropyridin-2-amine as a yellow oil. Yield: 95.7%.

**Example 1-2:** *N*-(2,2-difluoroethyl)-3-nitropyridin-2-amine

\[
\begin{align*}
\text{Cl} & \quad \text{NH} \\
\text{NO}_2 & \quad \text{NH} \\
\end{align*}
\]

The following compounds were obtained using the same procedure as in Example 1.

**Example 1-2:** *N*-(2,2-difluoroethyl)-3-nitropyridin-2-amine

\[
\begin{align*}
\text{Cl} & \quad \text{NH} \\
\text{NO}_2 & \quad \text{NH} \\
\end{align*}
\]
$C_7H_{11}F_2N_3O_2 = 203,15$  Mass spectrometry $M+1 = 204$

**Example 1-3**: $\text{N-cyclopropyl-3-nitropyridin-2-amine}$

\[ \text{NMR } ^1H (300 MHz / DMSO-d6) \delta (ppm) : 0,46(m,2H), 0,67(m,2H), 2,45(m,1H), 7,05(d,1H), 8,05(s,1H), 8,14(d,1H), 8,79(s,1H) \]

$C_8H_{10}N_3O_2 = 179,18$  Mass spectrometry $M+1 = 180,0$

**Example 1-4**: $\text{N-(cyclopropyl)-3-nitropyridin-4-amine}$

$C_8H_{10}N_3O_2 = 179,18$  Mass spectrometry $M+1 = 180,0$

**Example 1-5**: $\text{N-(cyclopropylmethyl)-3-nitropyridin-4-amine}$

$C_9H_{12}N_3O_2 = 184,18$  Mass spectrometry $M+1 = 185,2$

\[ \text{NMR } ^1H (300 MHz / DMSO-d6) \delta (ppm) : 0,20(m,2H), 0,39(m,2H), 1,05(m,1H), 3,17(t,2H), 6,94(d,1H), 8,15(d,1H), 8,33(s,1H), 8,91(s,1H) \]
Example 2: \( \text{N}\text{-cyclopropylmethyl)pyridine-2,3-diamine} \)

To a solution of 3.5 g (18.1 mM) of \( \text{N-}(\text{cyclopropylmethyl)-3-nitropyridin-2-amine} \) in 36 ml of methanol, were added 700 mg of palladium on carbon at 5%. The reaction mixture was stirred for 3 h at room temperature under hydrogen atmosphere at room pressure. The catalyst was filtrated on Celite and the filtrate was evaporated under vacuum to give 3.1 g of \( \text{N}^2\text{-}(\text{cyclopropylmethyl)pyridine-2,3-diamine} \) as a solid. Yield: 99.5%.

NMR \( ^1\text{H} \) (300 MHz / DMSO-d6) \( \delta \) (ppm): 0.00 (m, 2H), 0.24 (m, 2H), 0.88 (m, 1H), 2.96 (t, 2H), 4.5 (s, 2H), 5.37 (t, 1H), 6.15 (m, 1H), 6.44 (J 1H) 7.13 (1d, 1 H)

The following compounds were obtained using the same procedure as in Example 2.

Example 2-2: \( \text{N}^2\text{-}(2,2\text{-difluoroethyl)pyridine-2,3-diamine} \)

\( \text{C}_{7}\text{H}_{9}\text{F}_2\text{N}_3 = 173,16 \) Mass spectrometry \( M+1 = 174,1 \)

Example 2-3: \( \text{N}\text{-cyclopropylpyridine^S-diamine} \)
C₈H₉N₃ = 149,19 \quad \text{Mass spectrometry} \quad M+1 = 150,1

**Example 2-4**: \(\text{N}^4\)-cyclopropylpyridine-3,4-diamine

\[
\begin{align*}
\text{NMR} \ \ ^1\text{H} \ (300 \text{ MHz} / \text{DMSO-d6}) &\delta (\text{ppm}) : 0,29(\text{m,2H}), \ 0,61(171,2\text{H}), \\
&2,23(\text{TTi,1 H}), \ 4,40(\text{s,2H}), \ 5,65(\text{s,1 H}), \ 6,50(\text{d,1 H}), \ 7,49(\text{m,2H})
\end{align*}
\]

**Example 2-5**: \(\text{N}^4\)-fcyclopropylmethylJpyridine-S^-diamine

\[
\begin{align*}
\text{NMR} \ \ ^1\text{H} \ (300 \text{ MHz} / \text{DMSO-d6}) &\delta (\text{ppm}) : 0,02(\text{m,2H}), \ 0,28(\text{m,2H}), \\
&0,84(\text{m,1 H}), \ 2,74(\text{t,2H}), \ 4,41(\text{s,2H}), \ 5,19(\text{m,1 H}), \ 6,14(\text{d,1 H}), \ 7,35(\text{d,1 H}), \\
&7,41(\text{s,1H})
\end{align*}
\]

**Method A**

**Example 3**: 2-(4-chlorophenyl)-4-cyclopropylmethylpyrido[2,3- \text{b}]pyrazin-3(4H)-one

\[
\begin{align*}
\text{NMR} \ \ ^1\text{H} \ (300 \text{ MHz} / \text{DMSO-d6}) &\delta (\text{ppm}) : 0,02(\text{m,2H}), \ 0,28(\text{m,2H}), \\
&0,84(\text{m,1 H}), \ 2,74(\text{t,2H}), \ 4,41(\text{s,2H}), \ 5,19(\text{m,1 H}), \ 6,14(\text{d,1 H}), \ 7,35(\text{d,1 H}), \\
&7,41(\text{s,1H})
\end{align*}
\]

430 mg (2,63 mM) of \(\text{N}^4\)cyclopropylmethylOpyridine^S^-diamine and 485,4 mg (2,63 mM) of (4-chlorophenyl)(oxo)acetic acid in 6 ml of methanol were
refluxed for 16 h. A solid crystallized. The compound was filtered and washed with methanol to give
300 mg of 2-(4-chlorophenyl)-4-(cyclopropylmethyl)pyrido[2,3-f]pyrazin-3(4H)-one as a beige solid. Yield: 36.5%.

NMR $^1$H (300 MHz / CF3COOD) $\delta$ (ppm): 0.59 (m,4H), 1.23 (m,1 H), 4.44(d,2H), 7.44(d,2H), 7.83(m,1 H), 8.11(d,2H), 8.66(d,1H), 8.89(d,1H)

The following compounds were obtained using the same procedure as in Example 3.

**Example 3-2**: 2-(4-chlorophenyl)-4-ethylpyrido[2,3-b]pyrazin-3(4H)-one

NMR $^1$H (300 MHz / CF3COOD) $\delta$ (ppm): 0.18(t,3H), 3.30(q,2H), 6.16(d,2H), 6.55(m,1 H), 6.84(d,2H), 7.37(d,1 H), 7.63(d,1 H)

**Example 3-3**: 2-(4-fluorophenyl)-4-ethylpyrido[2,3-b]pyrazin-3(4H)-one

NMR $^1$H (300 MHz / DMSO-d6) $\delta$ (ppm): 1.30(t,3H), 4.47(q,2H), 7.36(t,2H), 7.51(m,1 H), 8.33(m,3H), 8.69(d,1 H)

**Example 3-4**: 4-ethyl-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one
NMR $^1$H (300 MHz / DMSO-d6) $\delta$ (ppm): 1.30(t,3H), 4.47(q,2H), 7.54(m,4H), 8.24(m,3H), 8.67(d,1H)

**Example 3-5**: 2-(4-chlorophenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4H)-one

NMR $^1$H (300 MHz / CF$_3$COOD) $\delta$ (ppm): 1.15(m,2H), 1.60(m,2H), 3.27(m,1H), 7.40(d,2H), 7.83(m,1H), 8.13(d,2H), 8.64(d,1H), 8.86(d,1H)

$C_{16}H_{12}ClN_3O = 297.74$  Mass spectrometry $M+1 = 298.0$

**Example 3-6**: 4-cyclopropyl-2-(4-fluorophenyl)pyrido[2,3-]jpyrazin-3(4H)-one

NMR $^1$H (300 MHz / CF$_3$COOD) $\delta$ (ppm): 1.10(m,2H), 1.57(m,2H), 3.23(m,1H), 7.06(m,2H), 7.79(m,1H), 8.15(m,2H), 8.39(d,1H), 8.83(d,1H)

$C_{16}H_{12}FN_3O = 281.28$  Mass spectrometry $M+1 = 282.1$
Example 3-7: 4-cyclopropylmethyl-2-(4-fluorophenyl)pyrido[2,3-Jb]pyrazin-3(4H)-one

NMR 1H (300 MHz / DMSO-d6) δ (ppm): 0.46(m,4H), 1.33 (m,1H), 4.34(d,2H), 7.34(t,2H), 7.49(m,1H), 8.30(m,3H), 8.65(d,1H)

Example 3-8: 2-(4-chlorophenyl)-4-(2,2-difluoroethyl)pyrido[2,3-/?]pyrazin-3(4H)-one

NMR 1H (300 MHz / DMSO-d6) δ (ppm): 4.88(td,2H), 6.41 (tt,1H), 7.59(m,3H), 8.28(m,3H), 8.66(d,1H)

Example 3-9: 3-(4-chlorophenyl)-1-cyclopropylpyrido[3,4-b]pyrazin-2(1H)-one
NMR $^1$H (300 MHz / DMSO-d6) $\delta$ (ppm): 0.97(m,2H), 1.36(m,2H), 3.12(m,1 H), 7.63(d,2H), 7.82(d,1 H), 8.29(d,2H), 8.66(d,1 H), 9.04(s,1H)

$C_{16}H_{12}ClN_3O = 297.74$  
Mass spectrometry M+1 = 298.0

**Example 3-10**: 1-cyclopropyl-3-(4-fluorophenyl)pyrido[3,4-f]pyrazin-2(1H)-one

![Chemical Structure](image)

$C_{16}H_{12}FN_3O = 281.28$  
Mass spectrometry M+1 = 282.0

**Example 3-11**: 1-cyclopropyl-3-phenylpyrido[3,4-b]pyrazin-2(1H)-one

![Chemical Structure](image)

$C_{16}H_{13}N_3O = 263.29$  
Mass spectrometry M+1 = 264.1

**Example 3-12**: 1-cyclopropyl-3-[4-(trifluoromethyl)phenyl]pyrido[3,4-/>]pyrazin-2(1H)-one

![Chemical Structure](image)

$C_{17}H_{12}F_3N_3O = 331.29$  
Mass spectrometry M+1 = 332.0
Example 3-13: 2-(4-chlorophenyl)-4-cyclopropyl-8-methylpyrido[2,3-fo]pyrazin-3(4H)-one

NMR $^1$H (300 MHz / DMSO-d6) δ (ppm): 0.92 (m, 2H), 1.25 (m, 2H), 2.69 (s, 3H), 3.08 (m, 1H), 7.36 (d, 1H), 7.61 (d, 2H), 8.34 (d, 2H), 8.52 (d, 1H)

C$_{17}$H$_{14}$ClN$_3$O = 311,77 Mass spectrometry M+1 = 312,0

m.p.: 159-163X

Example 3-14: 4-cyclopropyl-2-(4-fluorophenyl)-6-methylpyrido[2,3-b]pyrazin-3(4H)-one

C$_{17}$H$_{14}$FNN$_3$O = 295,31 Mass spectrometry M+1 = 296,0

Example 3-15: 2-(4-chlorobenzyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4H)-one

NMR $^1$H (300 MHz / CDCl$_3$) δ (ppm): 0.86 (q, 2H), 1.28 (q, 2H), 3.00 (m, 1H), 4.12 (s, 2H), 7.19 (171,3H), 7.30 (d, 2H), 8.02 (d, 1H), 8.50 (m, 1H)
Example 3-16: 2-(4-fluorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[
\begin{align*}
\text{C}_{16}\text{H}_{14}\text{F}\text{N}_3\text{O}_2 & = 299,3 \\
\text{Mass spectrometry } M+1 & = 300,0 \\
m.p.: & \text{ 124-127X}
\end{align*}
\]

Example 3-17: 4-butyl-2-(4-chlorophenyl)-pyrido[2,3-b]pyrazin-3(4H)-one

\[
\begin{align*}
\text{C}_{17}\text{H}_{16}\text{Cl}\text{N}_3\text{O} & = 313, 79 \\
\text{Mass spectrometry } M+1 & = 314,0
\end{align*}
\]

Example 3-18: 2-(4-chlorophenyl)-4-isopropyl-pyrido[2,3-b]pyrazin-3(4H)-one

NMR \[\text{^1H (300 MHz / DMSO-d6) } \delta \text{ (ppm): } 1.55(\text{d,}6\text{H}), 5.86(\text{m,}1\text{H}), 7.40(\text{t,t,}1\text{H}), 7.50(\text{d,}2\text{H}), 8.15(\text{d,}2\text{H}), 8.20(\text{d,}1\text{H}), 8.60(\text{d,}1\text{H})\]

\[
\begin{align*}
\text{C}_{16}\text{H}_{14}\text{ClN}_3\text{O} & = 299,76 \\
\text{Mass spectrometry } M+1 & = 299,7
\end{align*}
\]
Example 3-19: 4-cyclopropyl-2-(4-trifluoromethylphenyl)-pyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{17}\text{H}_{12}\text{F}_{3}\text{N}_{3}\text{O} = 331,29 \text{ Mass spectrometry } M+1 = 332,1 \]

Example 3-20: 4-cyclopropylmethyl-2-(4-trifluoromethylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{18}\text{H}_{14}\text{F}_{3}\text{N}_{3}\text{O} = 345,32 \text{ Mass spectrometry } M+1 = 346,1 \]

Example 3-21: 4-(2,2-difluoroethyl)-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{15}\text{H}_{n}\text{F}_{2}\text{N}_{3}\text{O} = 287,27 \text{ Mass spectrometry } = 288,0 \]
Example 3-22: 4-(2,2-difluoroethyl)-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[
\text{C}_{15}\text{H}_{10}\text{F}_{3}\text{N}_{3}\text{O} = 305.27 \quad \text{Mass spectrometry } M+1 = 306.0
\]

Example 3-23: 4-(2,2-difluoroethyl)-2-(4-trifluoromethylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[
\text{C}_{16}\text{H}_{10}\text{F}_{5}\text{N}_{3}\text{O} = 355.27 \quad \text{Mass spectrometry } M+1 = 356.0
\]

Example 3-24: 4-(2-methoxyethyl)-2-(4-trifluoromethylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[
\text{C}_{17}\text{H}_{14}\text{F}_{3}\text{N}_{3}\text{O}_{2} = 349.31 \quad \text{Mass spectrometry } M+1 = 350.1
\]
Example 3-25: 2-(4-chlorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one

C<sub>16</sub>H<sub>14</sub>CIN<sub>3</sub>O<sub>2</sub> = 315.76  Mass spectrometry M<sup>+</sup>1 = 316.0

Example 3-26: 4-(2-methoxyethyl)-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one

C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub> = 281.31  Mass spectrometry M<sup>+</sup>1 = 282.1

Example 3-27: 4-cyclopropyl-2-(4-trifluoromethylphenyl)-8-methylpyrido[2,3-b]pyrazin-3(4H)-one

C<sub>16</sub>H<sub>15</sub>CF<sub>3</sub>N<sub>3</sub>O = 370.3
C\textsubscript{18}H\textsubscript{14}F\textsubscript{3}N\textsubscript{3}O = 345,32  Mass spectrometry M+1 = 346,3

**Example 3-28**: 4-cyclopropyl-2-(4-fluorophenyl)-8-methylpyrido[2,3-b]pyrazin-3-(4H)-one

![Chemical structure](image)

C\textsubscript{17}H\textsubscript{15}FN\textsubscript{3}O = 295,32  Mass spectrometry M+1 = 296,1

**Example 3-29**: 4-cyclopropylmethyl-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one

![Chemical structure](image)

C\textsubscript{17}H\textsubscript{15}N\textsubscript{3}O = 277,33  Mass spectrometry M+1 = 278,1

**Example 3-30**: 2-(4-chlorophenyl)-4-cyclopropyl-7-methylpyrido[2,3-b]pyrazin-3(4H)-one

![Chemical structure](image)

C\textsubscript{17}H\textsubscript{14}ClN\textsubscript{3}O = 311,77  Mass spectrometry M+1 = 312,0
**Example 3-31**: 4-cyclopropyl-2-(4-fluorophenyl)-7-methylpyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{17}\text{H}_{14}\text{F}_3\text{N}_3\text{O} = 295.32 \]  
Mass spectrometry \( M+1 = 296.1 \)

**Example 3-32**: 2-(4-fluoro-phenyl)-4-isopropyl-pyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{17}\text{H}_{14}\text{F} \]  
Mass spectrometry \( M+1 = 284.1 \)

**Example 3-33**: 4-isopropyl-2-phenylpyrido[2,3-b]pyrazin-3(4W)-one

\[ \text{C}_{16}\text{H}_{15}\text{N}_3\text{O} = 265.31 \]  
Mass spectrometry \( M+1 = 266.1 \)

**Example 3-34**: 2-(4-chlorophenyl)-4-cyclopropyl-6-methylpyrido[2,3-b]pyrazin-3(4/V)-one

\[ \text{C}_{16}\text{H}_{15}\text{N}_3\text{O} = 265.31 \]  
Mass spectrometry \( M+1 = 266.1 \)
Example 3-35: 4-cyclopropyl-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one

Example 3-36: 4-cyclopropyl-2-(4-fluorophenyl)-6-methoxypyrido[2,3-b]pyrazin-3(4H)-one

Example 3-37: 4-cyclobutyl-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
Example 3-38: 2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one

Example 3-39: 2-(4-Fluorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one

Example 3-40: 4-(2-hydroxyethyl)-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one
Example 3-41: 2-(4-Chlorophenyl)-4-(3-hydroxypropyl)pyrido[2,3-b]pyrazin-3(4H)-one

Example 3-42: 2-(4-Fluorophenyl)-4-(3-hydroxypropyl)pyrido[2,3-b]pyrazin-3(4H)-one

Example 3-43: 4-(3-Hydroxypropyl)-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one
Example 3-44: 1-ethyl-3-(4-fluorophenyl)pyrido[2,3-b]pyrazin-2(1H)-one

Example 3-45: 2-(4-fluorophenyl)-4-[2-(diethylamino)ethyl]pyrido[2,3-b]pyrazin-3(4H)-one

Example 3-46: 2-(4-chlorophenyl)-4-[2-(diethylamino)ethyl]pyrido[2,3-fc]pyrazin-3(4H)-one
Method B

Example 4: 4-(cyclopropylmethyl)-2-hydroxypyrido[2,3-b]pyrazin-3(4H)-one

To 1.6 g (9.8 mM) of L-(cyclopropylmethyl)pyridine·S-diamine and 1.7 mL (9.8 mM) of diisopropylamine in 20 mL of dichloromethane were added, drop by drop, under stirring; at room temperature, 1.1 mL (9.8 mM) of ethyl chloro(oxo)acetate. The reaction mixture was stirred at room temperature for 16 h and water was added. The organic layer was separated and the aqueous layer was extracted twice with dichloromethane. The combined organic layer was washed with water, dried on anhydrous sodium sulfate and the solvent was removed under vacuum. The compound was further purified by silica gel column chromatography using dichloromethane/methanol (95/5) as eluant, which afforded after evaporation 700 mg of 4-(cyclopropylmethyl)-2-hydroxypyrido[2,3-b]pyrazin-3(4H)-one as a solid. Yield: 33%.
NMR $^1$H (300 MHz / DMSO-d6) $\delta$ (ppm): 0.19(m,4H), 1.03(m,1 H), 3.90(d,2H), 6.98(m,1 H), 7.29(d,1 H), 7.96(d,1 H), 11.94(S,1 H)

The following compounds were obtained using the same procedure as in Example 4.

**Example 4-2**: 4-(cyclopropyl)-2-hydroxypyrido[2,3-b]pyrazin-3(4/7)-one

![Chemical structure](image)

$C_{10}H_{9}N_{3}O_{2} = 203.2$  
Mass spectrometry $M+1 = 204.0$

**Example 5**: 2-bromo-4-(cyclopropylmethyl)pyrido[2,3-b]pyrazin-3(4A)-one

![Chemical structure](image)

700 mg (3.22 mM) of 4-(cyclopropylmethyl)-2-hydroxypyrido[2,3-fc]pyrazin-3(4H)-one and 972,3 mg (3,22mM) of phosphorus oxybromide at 95% in 10 ml of dichloroethane were refluxed for 16H under stirring. The reaction mixture was then basified with an aqueous solution of sodium carbonate and the aqueous layer was extracted with dichloromethane. The organic layer was separated, washed with water, dried on anhydrous sodium sulfate and the solvent was removed under vacuum. The compound was further purified by silica gel column chromatography, using dichloromethane as eluant, to give, after evaporation, 650 mg of 2-bromo-4-(cyclopropylmethyl)pyrido[2,3-fc-]pyrazin-3(4H)-one as a white solid. Yield: 66.5%.
The following compounds were obtained using the same procedure as in Example 5.

**Example 5-2**: 2-bromo-4-(cyclopropyl)pyrido[2,3-b]pyrazin-3(4H)-one

![Chemical Structure](image)

C_{10}H_{8}BrN_{3}O = 266.1  
Mass spectrometry M+1 = 267.0  
m.p.i 144-146°C

**Example 6**: 4-(cyclopropylmethyl)-2-(4-fluoro-2-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one

![Chemical Structure](image)

To 200 mg (0.71 mM) of 2-bromo-4-(cyclopropylmethyl)pyrido[2,3-b]pyrazin-3(4/-)-one and 25.3 mg (0.036 mM) of bis(triphenylphosphine) palladium(II)chloride in 1 ml of dimethylformamide were added 142.9 mg (0.93 mM) of (4-fluoro-2-methylphenyl)boronic acid, 0.1 ml of ethanol and 715 µl of a 2M aqueous solution of sodium carbonate. The reaction mixture was then refluxed for 20 h under stirring. Water and ethyle acetate were
The organic layer was separated, washed with water, dried on anhydrous sodium sulfate and the solvent was removed under vacuum. The compound was further purified by silica gel column chromatography, using dichloromethane as eluant, to give, after evaporation, 100 mg of 4-(cyclopropyl methyl)-2-(4-fluoro-2-methylphenyl)pyrido[2,3-\(b\)]pyrazin-3(4H)-one as a white solid. (Yield: 45,3%)

\[\text{C}_{18}\text{H}_{16}\text{F}_{3}\text{N}_{3}\text{O} = 309.34\]

Mass spectrometry M+1 = 310.1

The following compounds were obtained using the same procedure as in Example 6.

**Example 6-2**: 4-cyclopropyl-2-(4-fluoro-2-methylphenyl)pyrido[2,3-\(b\)]pyrazin-3(4W)-one

\[
\begin{array}{c}
\text{C}_{17}\text{H}_{14}\text{F}_{3}\text{N}_{3}\text{O} = 295.31\text{ Mass spectrometry M+1 = 296.1} \\
m.p.: 165-167°C
\end{array}
\]

**Example 6-3**: 2-(4-chloro-2-methylphenyl)-4-cyclopropylpyrido[2,3-\(b\)]pyrazin-3(4W)-one
Example 6-4: 4-cyclopropyl-2-(3-fluorophenyl)-pyrido[2,3-b]pyrazin-3(4H)-one

Example 6-5: 2-(3-chlorophenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4H)-one

Example 6-6: 4-cyclopropyl-2-(3-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
Example 6-7: 4-cyclopropylmethyl-2-(4-fluoro-2-methylphenyl)-pyrido[2,3-b]pyrazin-3(4A7)-one

Example 6-8: 4-cyclopropyl-2-(4-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one

Example 6-9: 4-cyclopropyl-2-[3-(trifluoromethyl)phenyl]pyrido[2,3-b]pyrazin-3(4H)-one
Example 6-10: 2-(2-Chlorophenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4H)-one

C_{16}H_{12}ClN_{3}O = 329,74  
Mass spectrometry M+1 = 330,1

Example 6-11: 4-Cyclopropyl-2-(2,4-dichlorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one

C_{16}H_{11}Cl_{2}N_{3}O = 332,18  
Mass spectrometry M+1 = 333,2

Example 6-12: 4-Cyclopropyl-2-(2,4,5-trifluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
Example 6-13: 4-Cyclopropyl-2-(2-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{16} \text{H}_{10} \text{F}_{3} \text{N}_{3} \text{O} = 317.27 \quad \text{Mass spectrometry} \; M+1 = 318.0 \]

Example 6-14: 4-Cyclopropyl-2-(4-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{17} \text{H}_{15} \text{N}_{3} \text{O}_{2} = 293.32 \quad \text{Mass spectrometry} \; M+1 = 294.1 \]

Example 6-15: 2-(4-Chloro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{17} \text{H}_{15} \text{N}_{3} \text{O}_{2} = 293.32 \quad \text{Mass spectrometry} \; M+1 = 294.1 \]
Example 6-16: 2-(2,4-Dichlorophenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one

Ci_7Hi_6ClN_3O = 313,78  Mass spectrometry  M+1 = 314,0

Example 6-17: 2-(4-Fluoro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one

Ci_6Hi_5ClN_3O = 297,33  Mass spectrometry  M+1 = 298,1

Example 6-18: 2-(2-Ethoxyphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
Example 6-19: 4-cyclopropyl-2-(6-methoxypyridin-3-yl)pyrido[2,3-b]pyrazin-3(4H)-one

Example 6-20: 4-cyclopropyl-2-(2-thienyl)pyrido[2,3-b]pyrazin-3(4W)-one

Example 6-21: 4-cyclopropyl-2-(2-furyl)pyrido[2,3-b]pyrazin-3(4W)-one
Example 6-22: 2-(4-chloro-2-methylphenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{14}\text{H}_{11}\text{N}_2\text{O}_2 = 253,26 \quad \text{Mass spectrometry} \quad \text{M}+1 = 254,0 \]

Example 6-23: 2-(4-fluoro-2-methylphenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{16}\text{H}_{14}\text{ClN}_2\text{O}_2 = 315,75 \quad \text{Mass spectrometry} \quad \text{M}+1 = 316,0 \]

Example 6-24: 2-(4-chloro-2-methylphenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[ \text{C}_{16}\text{H}_{14}\text{FNO}_2 = 299,3 \quad \text{Mass spectrometry} \quad \text{M}+1 = 300,1 \]
Example 6-25: 2-(4-fluoro-2-methylphenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[
\text{C}_7\text{H}_{16}\text{ClN}_3\text{O}_2 = 329.78 \quad \text{Mass spectrometry} \quad M+1 = 330.0
\]

Example 6-26: 4-cyclopropyl-2-(2,4-dimethylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one

\[
\text{C}_8\text{H}_{17}\text{FN}_3\text{O}_2 = 313.33 \quad \text{Mass spectrometry} \quad M+1 = 314.1
\]

BIOLOGICAL ASSAYS

The INS-1 cells were selected to evaluate compounds of the present invention for their superior response to glucose and other physiological and pharmacological insulin secretagogues.

Culture of pancreatic INS-1 cells
INS-1 cells were cultured in complete medium, RPMH 640 containing 1mM sodium pyruvate, 50µM 2-mercaptoethanol, 2mM glutamine, 10mM HEPES, 100IU/mL penicillin, and 100µg/ml streptomycin (CM), supplemented with 10mM glucose, and 10% (vol/vol) heat-inactivated fetal calf serum (FCS), as described by Asfari et al. (Endocrinology 130: 167-178, 1992).

Insulin secretion assay

INS-1 cells were plated and cultured in 48-well plates. After 2 days of culture, the medium was removed and cells were cultured for 24h with a medium change to 5mM glucose, 1% FCS. The cells were then washed with Krebs-Ringer Bicarbonate HEPES buffer (KRBH; 135mM NaCl; 3,6mM KCl; 5mM NaHCO3; 0,5mM NaH2PO4; 0,5mM MgCl2; 1,5mM CaCl2 and 10mM HEPES; pH 7,4) 0,1% BSA containing 2,8mM glucose and preincubated for 30 min at 37°C in the same buffer. The cells were then washed twice and incubated for 1h in KRBH 0,1% BSA containing 4,2mM glucose and different concentrations of the tested molecule. Insulin concentration in the collected supematants was measured with ELISA using rat insulin antibody (Insulin Rat Elit PLUS, cat. ref 10-145-01).

Insulin secretion results are expressed in % of control (glucose 4,2mM).

**Insulin secretion in INS-1 cells (glucose at 4,2 mM)**

<table>
<thead>
<tr>
<th>Example</th>
<th>% of ctrl at 10µM of cpd</th>
<th>% of ctrl at 50µM of cpd</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>241</td>
<td>398</td>
</tr>
<tr>
<td>3-2</td>
<td>240</td>
<td>263</td>
</tr>
<tr>
<td>3-3</td>
<td>235</td>
<td>251</td>
</tr>
<tr>
<td>3-4</td>
<td>226</td>
<td>302</td>
</tr>
<tr>
<td>3-5</td>
<td>418</td>
<td>610</td>
</tr>
</tbody>
</table>
Materials and Methods.

Islets isolation and treatments.

14 ± 3 weeks non-fasted NOSTZ (PORTHA et al., 1974) male rats (Charles Rivers-Domaine des Oncins, L’Arbresle, France) were anesthetised with sodium pentobarbital (Nembutal®: 45 mg/kg in 5 ml/kg administered intraperitoneally) and body temperature was maintained with a heat lamp.

Rat pancreatic islets of Langerhans were isolated from the pancreas of 8 rats by collagenase P (Boehringer, Meylan, France) digestion. Islets were purified by sedimentation in Hanks balanced salt solution [NaCl (137 mM); KCl (5.36 mM); MgSO₄, 7 H₂O (0.81 mM); Na₂HPO₄, 12 H₂O (0.34 mM); KH₂PO₄ (0.44 mM); CaCl₂, 2 H₂O (1.26 mM); NaHCO₃ (4.17 mM)] followed by Ficoll gradient separation. Islets were then hand-picked under stereoscopic microscope and batches of 3 islets were incubated for 90 minutes at 37°C with continuous shaking under a humidified condition (95% O₂, 5% CO₂) in 1 ml of Krebs/Hepes pH 7 solution [NaCl (115 mM), NaHCO₃ (24 mM), KCl (5 mM), MgCl₂ (1 mM), CaCl₂, 2 H₂O (1 mM), 0.2% of Bovine serum albumin (Fraction V, fatty acid free, Boehringer, Mannheim), 10 mM Hepes] containing the required glucose or compound concentration. Compounds
were dissolved in DMSO at 2.10-2M stock solutions. They were then diluted at the required concentration in Krebs/Hepes buffer containing the required glucose concentration.

At the end of incubation, media was collected and insulin levels were measured using ELISA (EUROBIO, Courtaboeuf, France).

<table>
<thead>
<tr>
<th>COMPOUND (M)</th>
<th>GLUCOSE 2.8 mM</th>
<th>GLUCOSE 8 mM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>10-4</td>
</tr>
<tr>
<td>3</td>
<td>100 ± 9</td>
<td>85 ± 8</td>
</tr>
<tr>
<td>3-7</td>
<td>100 ± 9</td>
<td>84 ± 10</td>
</tr>
</tbody>
</table>

Table - Dose response effect of compounds on insulin secretion in diabetic NOSTZ rat islets.

Islets were hand-picked and incubated in the presence of increasing concentrations of compounds in the presence of glucose at 2.8 or 8 mM. At the end of incubation, media was collected and insulin levels were measured using ELISA method. Results are expressed as % of glucose control (2.8 or 8 mM) and represent Means ± SEM.

In islets isolated from NOSTZ diabetic rats, the compounds showed no effect in the presence of a low, non-stimulatory, glucose concentration (2.8 mM), even at high concentration (10^{-4} M), while they potentiated insulin secretion in response to 8 mM glucose, a stimulatory glucose concentration. These results show that the effect of the compounds on the insulin secretion is dependent on the glucose level and suggest that a treatment with these compounds should avoid hypoglycemic risk.
Claims

1. A compound of the general formula (I)

\[
\begin{array}{c}
\text{Y} \\
\text{Z} \\
\text{W}
\end{array}
\]

wherein:

- one atom among \(X, Y, Z, W\) is a nitrogen atom and the others are a carbon atom substituted by a substituent selected from:
  - hydrogen,
  - \(T\);

A is:

- aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, arythioalkyl, aryalkylthioalkyl, heteroaryalkyl, heteroaryloxyalkyl, heteroaryalkoxyalkyl, heteroarythioalkyl, heteroaryalkylthioalkyl, heterocycloalkylalkyl, heterocycloalkyloxyalkyl, heterocycloalkylalkoxyalkyl, heterocycloalkylthioalkyl, heterocycloalkylalkylthioalkyl, heteroarylalkyl, heteroaryloxyalkyl, heteroarylalkoxyalkyl, heteroarylthioalkyl, heteroarylalkylthioalkyl, arylenyl, arylalkynyl; heteroaryl or heterocycloalkyl groups can include one or more heteroatom selected from \(N, O\) and \(S\);

- each of these groups can be optionally substituted by one or more substituents selected from \(T\);

R1 is:

- alkyl, alkylthioalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkyloxyalkyl, heterocycloalkylalkoxyalkyl, heterocycloalkylthioalkyl, heterocycloalkylalkylthioalkyl, \(R3R4N\)-alkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl;
each of these groups can be optionally substituted by one or more substituents selected from T;

T is:

hydroxy, thio, halogen, cyano, trifluoromethoxy, trifluoromethyl, carboxy, carboxy methyle, carboxyethyle, alkyle, cycloalkyl, alkoxy, alkylamino, aryle, aryle sulfonylalkyl, aryloxy, arylalkoxy, NR3R4, azido, nitro, guanidino, amidino, phosphono, oxo, carbamoyle, alkylsulfonyl, alkylsulfinyl, alkylthio, SF5, two T groups can form a methylenedioxy;

R3 and R4 are independently selected from:
hydrogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl;
R3 and R4 can also constitute an heterocycloalkyl group which can include one or more heteroatoms selected from N, O and S;
R3 and R4 independently can be optionally substituted by one or more substituents selected from T;

as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof.

2. A compound according to claim 1, wherein A is aryl, arylalkyl, heteroaryl which can include one or more heteroatoms selected from N, O and S; each of these groups can be optionally substituted by one or more substituents selected from T, as defined in claim 1.

3. A compound according to claim 2, wherein A is phenyl, benzyl, each of these groups can be optionally substituted by one or more substituents selected from T, as defined in claim 1.

4. A compound according to claim 1, wherein R1 is alkyl, alkyloxyalkyl, cycloalkyl, heterocycloalkyl, cycloalkylalkyl, heterocycloalkyloxyalkyl,
heterocycloalkylalkoxyalkyl, heterocycloalkylthioalkyl,
heterocycloalkylalkylthioalkyl, each of these groups can be optionally
substituted by one or more substituents selected from T, as defined in claim
1.

5. A compound according to claim 4, wherein R1 is alkyl, alkyloxyalkyl,
cycloalkyl, cycloalkylalkyl; each of these groups can be optionally substituted
by one or more substituents selected from T, as defined in claim 1.

10. A compound according to claim 5, wherein R1 is ethyl; isopropyl; butyl;
2,2-difluoroethyl; 2-methoxyethyl; cyclopropyl; cyclopropylmethyl, cyclobutyl.

7. A compound according to claim 1, wherein T is hydroxy, thio, halogen,
cyano, trifluoromethoxy, trifluoromethyl, carboxy, carboxy methyle,
carboxyethyle, alkyle, cycloalkyl, alkoxy, aryle, aryle sulfonylalkyl, arlyoxy,
arylalkoxy, NR3R4, azido, guanidino, amidino, phosphono, oxo, carbamoyle,
alkylsulfonyl, alkylsulfinyl, alkylthio, SF5, two T groups can form a
methylene dioxy.

8. A compound according to claim 1, wherein T is halogen, trifluoromethyl,
alkyle, cycloalkyl, alkoxy.

9. A compound according to claim 1, wherein T is methyl, cycloalkyl, Cl, F.

10. A compound according to claim 1, wherein R3 and R4 are
independently selected from lower alkyl, cycloalkyl.

11. A compound according to any of the preceding claims, selected from
the following compounds:

1-cyclopropyl-3-(4-fluorophenyl)pyrido[3,4-b]pyrazin-2(1/-/)-one
1-cyclopropyl-3-[4-(trifluoromethyl)phenyl]pyrido[3,4-b]pyrazin-2(1H)-one
1-cyclopropyl-3-phenylpyrido[3,4-b]pyrazin-2(1H)-one
2-(3-chlorophenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chloro-2-methylphenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorobenzyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-(2,2-difluoroethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropyl-6-methylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropyl-7-methylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropyl-8-methylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropylmethylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-ethylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-ethylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
3-(4-chlorophenyl)-1-cyclopropylpyrido[3,4-b]pyrazin-2(1/-/-)-one
4-(2,2-difluoroethyl)-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-(2,2-difluoroethyl)-2-(4-trifluoromethylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-(2-methoxyethyl)-2-(4-trifluoromethylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-(2-methoxyethyl)-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one
4-(cyclopropylmethyl)-2-(4-fluoro-2-methylphenyl)pyrido[2,3-ib]pyrazin-3(4H)-one
4-buty1-2-(4-chlorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclobutyl-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(3-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(3-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluoro-2-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluoro-2-methylphenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)-6-methoxypyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)-6-methylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)-7-methylpyrido[2,3-b]pyrazin-3(4/-/-)-one
4-cyclopropyl-2-(4-fluorophenyl)-8-methylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-methylphenyl)pyrido[2,3-b]pyrazin-3(4/-/-)-one
4-cyclopropyl-2-(4-trifluoromethylphenyl)-8-methylpyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-(4-trifluoromethylphenyl)-8-methylpyrido[2,3-b]pyrazin-3(4/-/-)-one
4-cyclopropyl-2-(4-trifluoromethylphenyl)-pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropyl-2-[3-(trifluoromethyl)phenyl]pyrido[2,3-b]pyrazin-3(4/-/-)-one
4-cyclopropylmethyl-2-(4-fluoro-2-methylphenyl)-pyrido[2,3-b]pyrazin-3(4/-/-)-one
4-cyclopropylmethyl-2-(4-fluorophenyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-cyclopropylmethyl-2-(4-fluoromethylphenyl)pyrido[2,3-b]pyrazin-3(4/-/-)-one
4-cyclopropylmethyl-2-(4-fluoro-2-methylphenyl)-pyrido[2,3-b]pyrazin-3(4/-/-)-one
4-cyclopropylmethyl-2-(3-(trifluoromethyl)phenyl)pyrido[2,3-b]pyrazin-3(4/-/-)-one
2-(2-Chlorophenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4/-/-)-one
4-Cyclopropyl-2-(2,4-dichlorophenyl)pyrido[2,3-b]pyrazin-3(4/-/-)-one
4-Cyclopropyl-2-(2,4,5-trifluorophenyl)pyrido[2,3-b]pyrazin-3(4/-/-)-one
4-Cyclopropyl-2-(2-methoxyphenyl)pyrido[2,3-b]pyrazin-3(4/-/-)-one
2-(4-Chloro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4/-/-)-one
2-(4-Chloro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4/-/-)-one
2-(4-Chloro-2-methylphenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4/-/-)-one
4-Cyclopropyl-2-(2-thienyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-Cyclopropyl-2-(2-furyl)pyrido[2,3-b]pyrazin-3(4/-/-)-one
2-(4-Chlorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Fluorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
4-(2-hydroxyethyl)-2-phenylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Chlorophenyl)-4-(3-hydroxypropyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-Fluorophenyl)-4-(3-hydroxypropyl)pyrido[2,3-b]pyrazin-3(4H)-one

A compound according to claim 11, selected from the following compounds:

12. A compound according to claim 11, selected from the following compounds:

2-(4-chlorobenzyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-(2,2-difluoroethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-(cyclopropylmethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropylmethylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-cyclopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-ethylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-chlorophenyl)-4-isopropylpyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-(2-methoxyethyl)pyrido[2,3-b]pyrazin-3(4H)-one
2-(4-fluorophenyl)-4-ethylpyrido[2,3-fc]pyrazin-3(4/-/)-one
2-(4-Fluorophenyl)-4-(2-hydroxyethyl)pyrido[2,3-b]pyrazin-3(4/-/)-one
4-cyclopropyl-2-(4-fluorophenyl)pyrido[2,3-6]pyrazin-3(4/-/)-one
4-cyclopropyl-2-ethylpyrido[2,3-/?]pyrazin-3(4H)-one
4-cyclopropylmethyl-2-(4-fluorophenyl)pyrido[2,3-6]pyrazin-3(4/-/)-one
4-ethyl-2-phenylpyrido[2,3-ι

as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof.

13. Process for the preparation of the compounds of general formula (I) according to any one of the preceding claims, the process comprising:
a) reacting a compound of formula (1)

\[
\begin{array}{c}
\text{X} \\
\text{Y} \\
\text{Z} \\
\text{W} \\
\text{Hal} \\
\text{NO}_2
\end{array}
\]

wherein:
X, Y, Z, W are as defined in claim 1;
Hal is a halogen atom, preferably Cl, Br;
with an amine R1-NH2, wherein R1 is as defined in claim 1, in the presence of a base in an inert solvent, to give a compound of formula (2)

\[
\begin{array}{c}
\text{Y} \\
\text{Z} \\
\text{W} \\
\text{NH} \\
\text{NO}_2
\end{array}
\]

(2)
b) reducing the compound of formula (2) with a metal, such as Zn, Sn or Fe, or metal in lower state of oxidation, such as Sn(II)chloride, in acids; or by catalytic hydrogenation with metal catalysts, such as Pd, Pt, Ni, preferably Pd on charcoal or Raney Nickel, in solvents, to obtain a compound of formula (3)
c) reacting the compound of formula (3) with an \( \alpha \)-keto acid derivative of the following formula

\[
\begin{align*}
\text{O} & \quad \text{A} \\
\text{R} & \quad \text{X}
\end{align*}
\]

wherein:
- A is as defined in claim 1;
- Rx is Hal, as above defined; or ORe, wherein Re is hydrogen, lower alkyl;

in a solvent, to obtain a compound of formula (I).

14. Process for the preparation of the compounds of general formula (I) according to any one of the claims 1-12, the process comprising:

a) reacting a compound of formula (1)

\[
\begin{align*}
\text{Y} & \quad \text{X} \\
\text{Z} & \quad \text{W}
\end{align*}
\]

(D)

wherein:
- X, Y, Z, W are as defined in claim 1;
- Hal is a halogen atom, preferably Cl, Br;

with an amine RI-NH\(_2\), wherein R1 is as defined in claim 1, in the presence of a base in an inert solvent, to give a compound of formula (2)
d) reducing the compound of formula (2) with a metal, such as Zn, Sn or Fe, or metal in lower state of oxidation, such as Sn(II)chloride, in acids; or by catalytic hydrogenation with metal catalysts, such as Pd, Pt, Ni, preferably Pd on charcoal or Raney Nickel, in solvents, to obtain a compound of formula (3)

(2)

\[
\begin{array}{c}
\text{R}_1 \\
\text{Y} \\
\text{Z} \\
\text{W} \\
\text{NH}_2 \\
\text{NO}_2
\end{array}
\]

(3)

e) reacting the compound of formula (3) with a compound of the following formula

\[
\begin{array}{c}
\text{R}_x \\
\text{O} \\
\text{R}_x \\
\text{O}
\end{array}
\]

wherein \( R_x \) is as above defined,
in the presence of a base, in an inert solvent, to obtain the compound of formula (5);

(5)

f) reacting the compound of formula (5) with a brominating agent, such as POBr\(_3\), in an inert solvent, to give the compound of formula (6)
5 g) reacting the compound of formula (6) with boronic acid derivatives or their esters, in the presence of a base and a catalyst, such as bis(triphenylphosphine) palladium(II) chloride, in an inert solvent, to obtain a compound of formula (I).

15. A compound of general formula (I) wherein X, Y, Z, W, A and R1 are as defined in claim 1, as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof, for the preparation of a medicament for the prevention and/or treatment of pathologies associated with hyperglycaemia.

16. A compound according to claim 15, for the preparation of a medicament that induces insulin secretion in response of glucose concentration.

17. A compound according to claims 15 or 16, for the preparation of a medicament suitable for the treatment of diabetes.

18. A compound according to claim 17, for the preparation of a medicament suitable for the treatment of type II diabetes.

19. A compound according to claims 15 or 16, for the preparation of a medicament suitable for the treatment of diseases chosen from dyslipidaemia and obesity.
20. A compound according to claims 15 to 18, for the preparation of a medicament suitable for the treatment of diseases chosen from diabetes related microvascular and macrovascular complications.

21. A compound according to claim 20, for which the said complications include arterial hypertension, atherosclerosis, inflammatory processes, microangiopathy, macroangiopathy, retinopathy and neuropathy.

22. A compound according to claim 15, for the preparation of a medicament suitable for reducing hyperglycaemia.

23. Use of a compound of general formula (I) according to any one of claims 1 to 12, wherein X, Y, Z, W, A and R1 are as defined in claim 1, as well as its racemic forms, tautomers, enantiomers, diastereomers, epimers and polymorphs, and mixtures thereof, and the pharmaceutically acceptable salts thereof, for the preparation of a medicament, for the prevention and/or treatment of pathologies associated with hyperglycaemia.

24. A pharmaceutical composition containing at least a compound of general formula (I) according to claims 1 to 12 and a pharmaceutically acceptable excipient.
**INTERNATIONAL SEARCH REPORT**

**A. CLASSIFICATION OF SUBJECT MATTER**

<table>
<thead>
<tr>
<th>Inv.</th>
<th>Classification</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C07D</td>
<td>471/04</td>
<td>Rij ε wijk</td>
</tr>
</tbody>
</table>

According to International Patent Classification (IPC) or to both national classification and IPC.

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched.

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, BEILSTEIN Data, CHEM ABS Data, PAJ

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X,P</td>
<td>WO 2008/043087 A (CV THERAPEUTICS INC) [US]; ZABLOCKI JEFF [US]; GLUSHKOV AUDREY [RU]; ZI</td>
<td>1-10,15,17-19,22-24</td>
</tr>
<tr>
<td></td>
<td>Compounds of formula I</td>
<td></td>
</tr>
<tr>
<td></td>
<td>WO 2007/122466 A (PFIZER PROD INC [US]; HUGHES ROBERT 0 [US]; BELL ANDREW SIMON [GB]; BR) 1 November 2007 (2007-11-01) Examples 13-21,23,27,29,30,32-38; pages 41-43</td>
<td>1,4,5,7-10,17-24</td>
</tr>
</tbody>
</table>

**X** Further documents are listed in the continuation of Box C. **X** See patent family annex.

- **A** document defining the general state of the art which is not considered to be of particular relevance.
- **E** earlier document but published on or after the international filing date
- **L** document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- **O** document referring to an oral disclosure, use, exhibition or other means
- **P** document published prior to the international filing date but later than the priority date claimed
- **T** later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- **X** document of particular relevance; the claimed invention cannot be considered without it
- **Y** document of particular relevance, the claimed invention cannot be considered if it is taken alone
- **Z** document member of the same patent family

Date of the actual completion of the international search

12 June 2009

Date of mailing of the international search report

19/06/2009

Name and mailing address of the ISA/Authorized officer

European Patent Office, P B 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016
Freelon, Didier

Form PCT/ISA/210 (second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>wc 2006/126081 A (PHARMACIA &amp; UPJOHN CO LLC [US] ; BELL ANDREW SIMON [GB] ; BENCSON ALAN GE) 30 November 2006 (2006-11-30) Compounds (II-H), (II-I), (II- J), (1 I-K); intermediates of steps 4, 5, page 54; example 2 and intermediates; example 3, step 5; examples 6, 15, 21, 24, 69, 77, 87, 90, 95; 118, 119, 121, 123, 126</td>
<td>1, 4, 7-10, 15-24</td>
</tr>
<tr>
<td>X</td>
<td>wc 99/54313 A (BOEHRINGER INGELHEIM PHARMA [DE]) 28 October 1999 (1999-10-28) examples 43, 44</td>
<td>1, 5, 7-10, 24</td>
</tr>
<tr>
<td>X</td>
<td>wc 97/24355 A (FUJISAWA PHARMACEUTICAL CO [JP] ; SHIMAZAKI NORHIKO [JP] ; SA WADA AKIHI) 10 July 1997 (1997-07-10) page 41; examples 3, 6, 8, 13</td>
<td>1, 2, 7-9, 17, 18, 24</td>
</tr>
</tbody>
</table>
### DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>WO 96/01825 A (FUJISAWA PHARMACEUTICAL CO [JP]; HEMMI MITSUE &amp; HF [JP]; SHIMAZAKI NOR) 25 January 1996 (1996-01-25) page 43; examples 1,2,3.1-3.3,3.5,3.6,3.11-3.13,3.14,4,5,6.1 -6.3,16.1,16.3-16.10,16.34-16.37,17,37,38, 43,45.10,45.12,45.14,45.19,45.20,47,49,54. 15,54.16,54.21,54.22,54.28,55,56,61,67,68. 1,68.4,68.15,68.16,69,78-80,86,88.1,88.3,8 9,94,98,100,103,-105,108,113</td>
<td>1-10,17,24</td>
</tr>
<tr>
<td>X</td>
<td>EP 0 920 867 A (FUJISAWA PHARMACEUTICAL CO [JP]) 9 June 1999 (1999-06-09) paragraph [0109]; examples</td>
<td>1-10,17</td>
</tr>
<tr>
<td>X</td>
<td>EP 0 008 864 A (FISONs PLC [GB]) 19 March 1980 (1980-03-19) page 7; examples 12-16,27,37,38,51,52</td>
<td>1</td>
</tr>
<tr>
<td>X</td>
<td>JP 05 155884 A (KYOWA HAKKO KOGYO KK) 22 June 1993 (1993-06-22) abstract; compounds 1-12</td>
<td>1,7,24</td>
</tr>
<tr>
<td>X</td>
<td>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002531035 Registry Numbers 860090, 902731</td>
<td>1-4,7,8</td>
</tr>
</tbody>
</table>

Form PCT/IB/210 (continuation of second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; VLADZIMIRS'KA, O. V. ET AL: &quot;Synthesis of thi azane-2,4-dione and its 3-derivatives&quot; XP002531039 retrieved from STN Database accession no. 1962:462750 abstract; RNs 92765-88-3,92799-14-9,93192-52-0,93227-08-8,93227-09-9,93227-70-4,96776-11-3,96984-3-4 &amp; DOPOVIDI AKADEMII NAUK UKRAINS'KOI RSR, (NO. 1), 80-1 CODEN: DUKRA4; ISSN: 0375-8435, 1962, ---------</td>
<td>1, 4, 5, 7</td>
</tr>
<tr>
<td>Category</td>
<td>Citation of document, with indication, where appropriate, of the relevant passages</td>
<td>Relevant to claim No</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------</td>
<td>---------------------</td>
</tr>
</tbody>
</table>

Form PCT/ISA/21O (continuation of second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>BARLIN, GORDON B. ET AL: &quot;Purines. VIII. Reactions of heterocyclic o-diamino compounds with acetylpuruvic acid ester&quot; CHEMISCHE BERICHTE, vol. 102, no. 12, 1969, pages 4032-4042, XF002531032 compounds 24,28 -----</td>
<td></td>
</tr>
<tr>
<td>A</td>
<td>WO 99/46260 A (ASTRA AB [SE]; KARABELAS KOSTAS [SE]; LOENN HANS [SE]; SJOE PETER [SE]) 16 September 1999 (1999-09-16) page 5; claims -----</td>
<td></td>
</tr>
<tr>
<td>Patent document</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>WO 2008043087</td>
<td>10-04-2008</td>
<td>AU 2007303056 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 20066665 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2008139570 Al</td>
</tr>
<tr>
<td>US 2008255130</td>
<td>16-10-2008</td>
<td>NONE</td>
</tr>
<tr>
<td>WO 2007122466</td>
<td>01-11-2007</td>
<td>AR 060525 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2007242555 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2649775 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EC 8088803 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2013208 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20080110930 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NL 2000583 C2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NL 2000583 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2007249615 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>UY 30291 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2644716 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2004193 A2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2009062280 Al</td>
</tr>
<tr>
<td>WO 2007020521</td>
<td>22-02-2007</td>
<td>NONE</td>
</tr>
<tr>
<td>WO 2006126083</td>
<td>30-11-2006</td>
<td>NONE</td>
</tr>
<tr>
<td>WO 2006126082</td>
<td>30-11-2006</td>
<td>CA 2608672 Al</td>
</tr>
<tr>
<td>WO 2006126081</td>
<td>30-11-2006</td>
<td>CA 2603830 Al</td>
</tr>
<tr>
<td>WO 2005067932</td>
<td>28-07-2005</td>
<td>AR 047085 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AT 367161 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2004313246 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>BR PI0418368 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2551639 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1901917 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 602004007693 T2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 1711184 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1711184 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2290782 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HR 20070430 T3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2007517800 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20060130159 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 1711184 E</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ZA 200606530 A</td>
</tr>
<tr>
<td>WO 2005021547</td>
<td>10-03-2005</td>
<td>NONE</td>
</tr>
<tr>
<td>WO 9954313</td>
<td>28-10-1999</td>
<td>AU 4030399 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2323606 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 1981683 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1071669 Al</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OP 2002512234 T</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 720301 B2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 1111297 A</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2241690 Al</td>
</tr>
<tr>
<td>Patent document</td>
<td>Publication date</td>
<td>Patent family member(s)</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>WO 9724355</td>
<td></td>
<td>CN 1205702</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69619702</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69619702</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 874845</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0874845</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2170286</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 9901038</td>
</tr>
<tr>
<td></td>
<td></td>
<td>IL 124673</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2000502699</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 874845</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6117875</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 698133</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2699295</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2194872</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1157617</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 1250776</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69529614</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69529614</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 770079</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 0770079</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2187561</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 1004483</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 77353</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 3206003</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 10502630</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 770079</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2170737</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TW 383307</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 6426345</td>
</tr>
<tr>
<td>EP 0920867</td>
<td>09-06-1999</td>
<td>NONE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 338379</td>
</tr>
<tr>
<td></td>
<td></td>
<td>FI 792507</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GR 69706</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NO 792653</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PT 70064</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 4296114</td>
</tr>
<tr>
<td>JP 5155884</td>
<td>22-06-1993</td>
<td>NONE</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2004082784</td>
</tr>
<tr>
<td>WO 9946260</td>
<td>16-09-1999</td>
<td>AU 2863899</td>
</tr>
</tbody>
</table>